Your email has been successfully added to our mailing list.

×
0.00139211136890957 0.00563341067285389 0.00659860788863104 0.0159721577726218 0.0148491879350348 0.0222737819025522 0.0338747099767982 0.0403712296983759
Stock impact report

Sangamo teams up with Novartis in neurodevelopmental disorders [Seeking Alpha]

Sangamo Therapeutics, Inc. (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
Company Research Source: Seeking Alpha
Sangamo Therapeutics(NASDAQ:SGMOcollaborate(NYSE:NVSUnder the terms of the three-year agreement, NVS will have exclusive rights to ZFP-TFs for three undisclosed genes and the option to license SGMO's proprietary adeno-associated viruses (AAVs).NVS will pay SGMO $75M upfront, up to $720M in milestones and tiered high single-digit-to-sub-teen double-digit royalties on net sales on commercialized products from the collaboration.SGMO is up8%1% Show less Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SGMO alerts

from News Quantified
Opt-in for
SGMO alerts

from News Quantified